157 related articles for article (PubMed ID: 31198545)
1. Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
Rottembourg J; Menegaux F
Clin Kidney J; 2019 Jun; 12(3):433-436. PubMed ID: 31198545
[TBL] [Abstract][Full Text] [Related]
2. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
3. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
[TBL] [Abstract][Full Text] [Related]
4. Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease.
Ding Y; Zou Q; Jin Y; Zhou J; Wang H
Int Urol Nephrol; 2020 Jan; 52(1):155-159. PubMed ID: 31686279
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
6. Integrated transcriptomic and proteomic analyses for the characterization of parathyroid oxyphil cells in uremic patients.
Mao J; You H; Wang M; Ni L; Zhang Q; Zhang M; Chen J
Amino Acids; 2022 May; 54(5):749-763. PubMed ID: 35348903
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA sequencing reveals transdifferentiation of parathyroid chief cells into oxyphil cells in patients with uremic secondary hyperparathyroidism.
Mao J; You H; Wang M; Ba Y; Qian J; Cheng P; Lu C; Chen J
Kidney Int; 2024 Mar; 105(3):562-581. PubMed ID: 38142040
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression by oxyphil and chief cells of human parathyroid glands.
Ritter CS; Haughey BH; Miller B; Brown AJ
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1499-505. PubMed ID: 22585091
[TBL] [Abstract][Full Text] [Related]
9. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
10. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
11. The oxyphil cell in abnormal parathyroid glands. A study of 114 cases.
Allen TB; Thorburn KM
Arch Pathol Lab Med; 1981 Aug; 105(8):421-7. PubMed ID: 6894851
[TBL] [Abstract][Full Text] [Related]
12. Functioning oxyphil cell adenoma in a patient with secondary hyperparathyroidism.
Misonou J; Ishikura H; Aizawa M; Ohira S
Acta Pathol Jpn; 1987 Aug; 37(8):1357-66. PubMed ID: 3314334
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
[TBL] [Abstract][Full Text] [Related]
14. [New Developments in CKD-MBD. Cell Biology of parathyroid in CKD].
Kakuta T; Sawada K
Clin Calcium; 2014 Dec; 24(12):1801-8. PubMed ID: 25423925
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
16. [Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl].
Tominaga Y
Clin Calcium; 2009 Apr; 19(4):545-50. PubMed ID: 19329834
[TBL] [Abstract][Full Text] [Related]
17. Comparative proteomic analysis of chief and oxyphil cell nodules in refractory uremic hyperparathyroidism by iTRAQ coupled LC-MS/MS.
Li S; Mao J; Wang M; Zhang M; Ni L; Tao Y; Huang B; Chen J
J Proteomics; 2018 May; 179():42-52. PubMed ID: 29526777
[TBL] [Abstract][Full Text] [Related]
18. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
[TBL] [Abstract][Full Text] [Related]
19. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Tominaga Y; Matsuoka S; Uno N; Sato T
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
[TBL] [Abstract][Full Text] [Related]
20. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
